Oakworth Capital’s Tvardi Therapeutics TVRD Stock Holding History

Oakworth Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-17	Closed	-$12K	–	661
2019 Q1	$12K	Buy	+17	New	+$10.2K	﹤0.01%	436

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Oakworth Capital's TVRD Position: Q2 2019 in Review

Oakworth Capital sold out of Tvardi Therapeutics (TVRD) in Q2 2019, closing a stake of 17 shares — an estimated $12K sold.

Oakworth Capital first reported a position in TVRD in Q1 2019 and held it in 1 quarter. The position peaked at $12K in Q1 2019. 126 funds tracked by Wall St. Rank hold TVRD as of Q2 2019.

Oakworth Capital reported no remaining Tvardi Therapeutics position as of Q2 2019 after selling out during the quarter.
Oakworth Capital sold 17 Tvardi Therapeutics shares in Q2 2019, an estimated $12K.
Oakworth Capital first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 1 quarter.
Oakworth Capital's Tvardi Therapeutics position peaked at $12K in Q1 2019.
126 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2019.

Based on Oakworth Capital's 13F filing for Q2 2019, filed 2 Aug 2019.